CORDIS Project
Funding breakdown and partner intelligence are Premium
Sign in and upgrade to Premium for EU contribution totals, consortium analytics, OpenAlex research context, and AI summaries. · 0 consortium intelligence fields visible of 1
Start free • Cancel anytime • 14-day refund guarantee
This project proposes a novel class of immunotherapeutics using oligonucleotides to enhance anti-tumor immunity by modulating immune checkpoint receptors. It aims to develop effective and safe treatments for cancer by utilizing nanoparticles for delivery and testing in pre-clinical models.
Tumours escape proper immune response by propagating immune suppression.
Immunotherapy aims to enhance anti-tumour immunity.
This highly relevant research area arose recently from advantages in immunology, genetics and oncology.
Currently, immunotherapeutics are either protein (e.g. antibodies) or cell-based (e.g. cancer vaccines) and promising approaches target immune checkpoint control, a mechanism crucial for anti-tumour T cell activity.Here, development of a completely new class of immunothe…
FRAUNHOFER GESELLSCHAFT ZUR FORDERUNG DER ANGEWANDTEN FORSCHUNG EV
Partner organizations (coordinator is shown above), with normalized type and CORDIS activity type. Guests see up to 4 partners.
Canada, Hamilton
Type: University / higher education
Activity type: Higher or Secondary Education Establishments
SME: No
Similar projects, consortium collaboration history, frequent partners, and OpenAlex research context.
Guests see up to 5 EuroSciVoc fields.
Guests see up to 5 topics.
